newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports Full Year 2025 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underwayADC